BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Head and neck cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for head and neck cancer: 424 (262 sponsors; 54 newly posted in the last 180 days, 20 stopped in the last 180 days; 27 new-entrant sponsors). Momentum score 9.3, rank 75 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 6, Phase 1 144, Phase 2 173, Phase 3 47, Phase 4 5, N/A 49.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Sichuan Baili Pharmaceutical Co., Ltd. | 24 | P2 12, P1 8, P3 4 | 5 | 7 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | 6 | P3 4, P2 2 | 3 | 0 |
| AstraZeneca AZN | 11 | P2 3, P3 3, NA 1, P1 4 | 0 | 2 |
| Exelixis EXEL | 6 | P3 2, P1 3, P4 1 | 0 | 2 |
| Genmab GMAB | 4 | P3 2, P2 2 | 0 | 0 |
| Lepu Biopharma Co., Ltd. | 4 | P2 2, P3 2 | 0 | 0 |
| Akeso | 3 | P2 1, P3 2 | 0 | 2 |
| Rakuten Medical, Inc. | 3 | P3 2, P2 1 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 7 | P2 6, P3 1 | 0 | 1 |
| Bicara Therapeutics BCAX | 3 | P2 1, P3 1, P1 1 | 1 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3 | P2 1, NA 1, P3 1 | 0 | 2 |
| Daiichi Sankyo | 3 | P3 1, P2 2 | 0 | 0 |
| GlaxoSmithKline | 3 | P3 1, P1 1, P2 1 | 0 | 0 |
| Hansoh BioMedical R&D Company | 3 | P2 2, P3 1 | 1 | 0 |
| Jazz Pharmaceuticals JAZZ | 3 | P3 1, NA 1, P2 1 | 1 | 1 |
| MediLink Therapeutics (Suzhou) Co., Ltd. | 3 | P2 2, P3 1 | 0 | 0 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | 3 | P2 2, P3 1 | 2 | 0 |
| Aveta Biomics, Inc. | 2 | P2 1, P3 1 | 1 | 1 |
| Beijing Konruns Pharmaceutical Co., Ltd. | 2 | P3 1, P2 1 | 0 | 1 |
| Inhibrx Biosciences, Inc INBX | 2 | P2 1, P3 1 | 0 | 0 |
| Janssen Research & Development, LLC | 2 | P2 1, P3 1 | 0 | 0 |
| Johnson & Johnson Enterprise Innovation Inc. JNJ | 2 | P3 1, P1 1 | 0 | 0 |
| Qilu Pharmaceutical Co., Ltd. | 2 | P3 1, P1 1 | 0 | 0 |
| AVEO Pharmaceuticals, Inc. | 1 | P3 1 | 0 | 0 |
| BioNTech SE BNTX | 1 | P3 1 | 0 | 0 |
Recently stopped trials
- NCT04428151 Merck Sharp & Dohme LLC - terminated: Business Reasons Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monother
- NCT05462873 Novartis Pharmaceuticals - terminated: Business decision and not related to safety concerns A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors
- NCT04868877 Merus B.V. - terminated: The Sponsor terminated the trial early for strategic business reasons. This isn't related to any safety/efficacy/clinical activity/benefit-r Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Soli
- NCT03444701 Eisai Co., Ltd. - terminated: The trial was prematurely terminated due to the sponsor's decision. A Study of E7130 in Participants With Solid Tumors
- NCT06091930 Boehringer Ingelheim - terminated: Sponsor decision A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Can
- NCT03881488 Compass Therapeutics - terminated: The combination therapy arm of the study with pembrolizumab did not yield an efficacy signal, so enrollment into the combination therapy arm Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metasta
- NCT05048368 Sunshine Lake Pharma Co., Ltd. - withdrawn: Study was withdrawn per sponsor decision after recruitment opened with no participants enrolled. Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
- NCT04844073 Takeda - terminated: Sponsor decision based on limited anti-cancer activity of TAK-186. A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
- NCT04630353 AstraZeneca - terminated: Sponsor decision. A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer
- NCT06790966 PDS Biotechnology Corp. - terminated: The study is being discontinued solely based on financial constraints and is not related to the safety of study participants, the investigat Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- NCT04949256 Merck Sharp & Dohme LLC - terminated: Trial was rendered as cancelled work ongoing in the book of business. Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Me
- NCT05827614 Boundless Bio, Inc. - terminated: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safe Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With
- NCT05572684 NextCure, Inc. - terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Meta
- NCT03281369 Hoffmann-La Roche - terminated: The study was closed because the sponsor decided not to continue the development of certain treatment combinations. A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metasta
- NCT06022757 Evopoint Biosciences Inc. - terminated: Strategic decision by Sponsor. Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-22 est. | P2 | Shanghai Henlius Biotech | NCT06839066 A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy | Nasopharyngeal Carcinoma (NPC) | recruiting | 70 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05054439 A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC | Head and Neck Squamous Cell Carcinoma | active not recruiting | 45 |
| 2026-12 est. | P2 | Aveta Biomics, Inc. | NCT05312710 Safety and Efficacy of APG-157 in Head and Neck Cancer | Head and Neck Cancer; Squamous Cell Carcinoma of Oral Cavity; Squamous Cell Carcinoma of the Orophar | active not recruiting | 24 |
| 2026-12 est. | P1/P2 | AP Biosciences Inc. | NCT05473156 A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion | Locally Advanced or Metastatic Solid Tumors; Non Small Cell Lung Cancer (NSCLC); Head and Neck Squam | recruiting | 168 |
| 2026-12 est. | P1/P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05668858 A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Head and Neck | active not recruiting | 70 |
| 2026-12 est. | P1/P2 | TiumBio Co., Ltd. | NCT05784688 Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | Solid Tumor; Biliary Tract Cancer; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer | recruiting | 140 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT05956587 A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tum | Non-small Cell Lung Cancer; Nasopharyngeal Carcinoma | recruiting | 121 |
| 2026-12 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06006169 A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | Head and Neck Squamous Cell Carcinoma | recruiting | 186 |
| 2026-12 est. | P1/P2 | Theravectys S.A. | NCT06319963 A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | HPV-Related Cervical Carcinoma; HPV Positive Oropharyngeal Squamous Cell Carcinoma | recruiting | 72 |
| 2026-12 est. | P1/P2 | SCG Cell Therapy Pte. Ltd. | NCT06505551 Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | HPV-Related Squamous Cell Carcinoma; HPV-Related Cervical Squamous Cell Carcinoma; HPV-Related Vulva | not yet recruiting | 66 |
| 2026-12 est. | P1/P2 | Akeso | NCT06943820 AK129 Combination Therapy for Advanced Solid Tumors | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC); Colorectal | recruiting | 230 |
| 2026-12 est. | P1/P2 | One-carbon Therapeutics AB | NCT07151040 Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | Solid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck; Non-Small Cell Lung | recruiting | 43 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-15 est. | P1/P2 | GV20 Therapeutics | NCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Solid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma; | recruiting | 365 |
| 2026-12-30 est. | P2 | NATCO Pharma Ltd. | NCT05283226 Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous | Carcinoma; Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma | recruiting | 21 |
| 2026-12-31 est. | P1/P2 | OncoC4, Inc. | NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carc | active not recruiting | 733 |
| 2026-12-31 est. | P1/P2 | BicycleTx Limited | NCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | Advanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Cancer | active not recruiting | 288 |
| 2026-12-31 est. | P2 | Valenta Pharm JSC | NCT06843018 Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Topical Spray, in the Treatment of Acute Infectious a | Pharyngitis Acute; Pharyngitis; Nasopharyngitis; Exacerbation of Chronic Pharyngitis | recruiting | 300 |
| 2027-01 est. | P3 | Akeso | NCT06601335 A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | Head and Neck Squamous Cell Carcinoma | recruiting | 510 |
| 2027-01-30 est. | P1/P2 | Psivac Ltd | NCT06549946 Ixovex-1 Single Agent and Combination Therapy | Solid Tumor; Head and Neck Cancer | recruiting | 18 |
| 2027-02 est. | P1/P2 | GI Innovation, Inc. | NCT07172802 A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor; Metastatic Solid Tumor; Non-small Cell Lung Cancer (NSCLC); Head and Neck (HNS | recruiting | 102 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06668961 A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cel | Head and Neck Squamous Cell Carcinoma | active not recruiting | 48 |
| 2026-11 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | Nasopharyngeal Carcinoma | active not recruiting | 386 |
| 2026-11 est. | P2 | MediLink Therapeutics (Suzhou) Co., Ltd. | NCT06107686 A Study of YL202 in Selected Patients With Advanced Solid Tumors | NSCLC; Breast Cancer; HNSCC; Locally Advanced or Metastatic Solid Tumors | recruiting | 200 |
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-10-01 | P1/P2 | Merus B.V. | NCT04868877 Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and | terminated | 194 |
| 2026-10 est. | P2 | Vyriad, Inc. | NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Melanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Cancer | active not recruiting | 87 |
| 2026-09-22 est. | P1/P2 | ImmVira Pharma Co. Ltd | NCT04370587 A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Me | Solid Tumor; Melanoma; HNSCC; Sarcoma; Squamous Cell Carcinoma; NSCLC | recruiting | 30 |
| 2026-09-10 | P2 | GlaxoSmithKline | NCT06062420 A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of | Neoplasms, Head and Neck | active not recruiting | 316 |
| 2026-09 est. | P3 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | NCT05717764 Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic | Recurrent Metastatic Nasopharyngeal Carcinoma | not yet recruiting | 500 |
| 2026-08-25 | P3 | PDS Biotechnology Corp. PDSB | NCT06790966 Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Cancer; Metastatic Head and Neck Cancer; HPV Positive Oropharyngeal Squamous | terminated | 12 |
| 2026-07-30 est. | P2 | Shanghai Institute Of Biological Products | NCT06194656 Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | recruiting | 81 |
| 2026-07-01 est. | P1/P2 | Scancell Ltd SCNLD | NCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer | Triple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamous | recruiting | 168 |
| 2026-07 est. | P1/P2 | CJ Bioscience, Inc. | NCT05877430 Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NSCLC; HNSCC; Melanoma; Metastatic Cancer; Advanced Solid Tumor; Advanced Cancer | recruiting | 160 |
| 2026-06-17 | P1/P2 | Precision Biologics, Inc DTIL | NCT03476681 Study of NEO-201 in Solid Tumors Expansion Cohorts | Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Cancer | active not recruiting | 121 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-06 est. | P1/P2 | Volastra Therapeutics, Inc. | NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Advanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancer | recruiting | 200 |
| 2026-06 est. | P1/P2 | Rakuten Medical, Inc. | NCT04305795 An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors | Recurrent Head and Neck Squamous Cell Carcinoma; Metastatic Head-and-neck Squamous-cell Carcinoma; L | active not recruiting | 23 |
| 2026-06 est. | P2 | Sound Pharmaceuticals, Incorporated SOGP | NCT01451853 SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss | Lung Cancer; Head and Neck Cancer; Hearing Loss; Ototoxicity; Tinnitus; Neuropathy | withdrawn |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "head and neck cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.